BANGALORE-based Biocon has decided to license some of the intellectual
properties (IPs) which it acquired from Nobex Inc, according to the
companyâ€™s annual report for 2006-07.
Biocon got a basket of IPs got when it emerged as the successful bidder for the assets of Nobex. These include technologies for oral insulin, oral BNP, basal insulin and Apaza. Biocon had a total commitment of Rs 49.6 crore in Nobex.
Of this basket, Bioconâ€™s board of directors had as of October 2006 decided to lease out Apaza. Consequently Biocon has begun amortising the cost of acquisition of the Apaza IP over its estimated useful life of five years and has provided for Rs 90 lakh in the accounts for the year ended March 31, 2007. The other IPs from Nobex are being carried at cost in the balance sheet.
Another area where Biocon is keen to make its presence felt is enzyme solutions notably in case of bio-fuels.
India has grown to be a highly regarded destination for international trade in recent years, and the pandemic has only caused greater interest in India in this aspect. According to figu More
Helplinelaw can set up your session with quality and experienced lawyers to discuss and resolve your legal matters. You can avail consultation in form of sending questions, phone call or webchat discussion More